The estimated Net Worth of Dennis Podlesak is at least $1.88 Millón dollars as of 15 September 2022. Mr. Podlesak owns over 78,815 units of Syndax Pharmaceuticals Inc stock worth over $1,508,084 and over the last 8 years he sold SNDX stock worth over $0. In addition, he makes $369,456 as Independent Chairman of the Board at Syndax Pharmaceuticals Inc.
Dennis has made over 2 trades of the Syndax Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 78,815 units of SNDX stock worth $498,111 on 15 September 2022.
The largest trade he's ever made was exercising 78,815 units of Syndax Pharmaceuticals Inc stock on 15 September 2022 worth over $498,111. On average, Dennis trades about 6,627 units every 37 days since 2016. As of 15 September 2022 he still owns at least 82,319 units of Syndax Pharmaceuticals Inc stock.
You can see the complete history of Mr. Podlesak stock trades at the bottom of the page.
Dennis G. Podlesak serves as Independent Chairman of the Board of the Company. Mr. Podlesak has served as a partner at Domain Associates, LLC, a life science-focused venture capital firm. While at Domain, Mr. Podlesak served as the Chairman of the board of Tobira Therapeutics, a publicly traded biopharmaceutical company that was acquired by Allergan plc in November 2016. Mr. Podlesak also served on the board of Avanir Pharmaceuticals, a publicly traded biopharmaceutical company, through its acquisition by Otsuka Pharmaceuticals in January 2015 and was on the board of Rightcare Solutions, which was acquired by Cardinal Health’s Naviheath division in December 2015. Mr. Podlesak was also the founder and the Chief Executive Officer of Calixa Therapeutics, Inc., a privately held biopharmaceutical company, that was acquired by Cubist Pharmaceuticals and Mr. Podlesak was the Executive Chairman of Corthera, Inc., a privately held biopharmaceutical company, which was acquired by Novartis AG. Earlier in his career, Mr. Podlesak served as the Founder and Chief Executive Officer of Cerexa, Inc., a privately held biotechnology company, which became a wholly owned subsidiary of Forest Laboratories, Inc. after being acquired by Forest. Prior to Cerexa, Mr. Podlesak served as the Chief Executive Officer of Peninsula Pharmaceuticals Inc., a privately held pharmaceutical company, and led the sale of Peninsula to Johnson & Johnson's Ortho-McNeil Pharmaceutical subsidiary. Prior to joining Peninsula, Mr. Podlesak held various executive management positions at Novartis AG, a publicly traded healthcare company, Allergan, plc, a publicly traded healthcare company and Smith Kline Beecham (now GlaxoSmithKline plc, a publicly traded pharmaceutical company). Mr. Podlesak is the Chairman of Adynxx and serves on other private company boards. Mr. Podlesak received a B.A. and an M.B.A. from Pepperdine University.
As the Independent Chairman of the Board of Syndax Pharmaceuticals Inc, the total compensation of Dennis Podlesak at Syndax Pharmaceuticals Inc is $369,456. There are 5 executives at Syndax Pharmaceuticals Inc getting paid more, with Michael Metzger having the highest compensation of $2,696,890.
Dennis Podlesak is 62, he's been the Independent Chairman of the Board of Syndax Pharmaceuticals Inc since 2008. There are 3 older and 14 younger executives at Syndax Pharmaceuticals Inc. The oldest executive at Syndax Pharmaceuticals Inc is Dr. Michael L. Meyers M.D., Ph.D., 70, who is the Chief Medical Officer & Sr. VP.
Dennis's mailing address filed with the SEC is C/O SYNDAX PHARMACEUTICALS, INC., 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM, MA, 02451.
Over the last 9 years, insiders at Syndax Pharmaceuticals Inc have traded over $1,950,406 worth of Syndax Pharmaceuticals Inc stock and bought 210,921 units worth $2,347,816 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Luke Evnin y Briggs Morrison. On average, Syndax Pharmaceuticals Inc executives and independent directors trade stock every 50 days with the average trade being worth of $745,679. The most recent stock trade was executed by Keith A. Goldan on 14 June 2024, trading 1,250 units of SNDX stock currently worth $25,038.
syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.
Syndax Pharmaceuticals Inc executives and other stock owners filed with the SEC include: